| # | Title | Journal | Year | Citations |
|---|
| 1 | Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations | Prostate | 1983 | 974 |
| 2 | Family history and the risk of prostate cancer | Prostate | 1990 | 609 |
| 3 | Molecular characterization of human prostate carcinoma cell lines | Prostate | 2003 | 555 |
| 4 | The zonal anatomy of the prostate | Prostate | 1981 | 521 |
| 5 | Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer | Prostate | 2004 | 475 |
| 6 | Etiology and disease process of benign prostatic hyperplasia | Prostate | 1989 | 453 |
| 7 | Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation | Prostate | 1993 | 407 |
| 8 | Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model | Prostate | 2003 | 402 |
| 9 | The TNM classification of prostate cancer | Prostate | 1992 | 383 |
| 10 | Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers | Prostate | 1986 | 367 |
| 11 | PC3 is a cell line characteristic of prostatic small cell carcinoma | Prostate | 2011 | 365 |
| 12 | Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis | Prostate | 2014 | 352 |
| 13 | Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement | Prostate | 1987 | 330 |
| 14 | LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis | Prostate | 2000 | 328 |
| 15 | Antagonistic effect of androgen on prostatic cell death | Prostate | 1984 | 327 |
| 16 | Radiation therapy for carcinoma of the prostate | Prostate | 1981 | 324 |
| 17 | The prostate: An increasing medical problem | Prostate | 1990 | 321 |
| 18 | Prostate antigen: A new potential marker for prostatic cancer | Prostate | 1981 | 319 |
| 19 | Increased Nox1 and hydrogen peroxide in prostate cancer | Prostate | 2005 | 309 |
| 20 | New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens | Prostate | 1983 | 305 |
| 21 | Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo | Prostate | 2001 | 292 |
| 22 | Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy | Prostate | 2011 | 287 |
| 23 | High-grade prostate cancer is associated with low serum testosterone levels | Prostate | 2001 | 280 |
| 24 | Androgen deprivation therapy for prostate cancer: Current status and future prospects | Prostate | 2004 | 279 |
| 25 | p53 oncogene mutations in three human prostate cancer cell lines | Prostate | 1993 | 276 |
| 26 | Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer | Prostate | 2011 | 273 |
| 27 | Structural heterogeneity and protein composition of exosome‐like vesicles (prostasomes) in human semen | Prostate | 2009 | 271 |
| 28 | Androgen-repressed messages in the rat ventral prostate | Prostate | 1986 | 254 |
| 29 | Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration | Prostate | 1989 | 246 |
| 30 | Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging | Prostate | 1985 | 243 |
| 31 | Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies | Prostate | 2010 | 241 |
| 32 | TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients | Prostate | 2011 | 239 |
| 33 | Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer | Prostate | 2010 | 233 |
| 34 | The proliferative function of basal cells in the normal and hyperplastic human prostate | Prostate | 1994 | 231 |
| 35 | CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12 | Prostate | 2006 | 229 |
| 36 | Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis | Prostate | 2009 | 227 |
| 37 | Proteomic analysis of human prostasomes | Prostate | 2003 | 226 |
| 38 | Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion | Prostate | 2006 | 225 |
| 39 | High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer | Prostate | 2011 | 224 |
| 40 | Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: Apoptotic bodies, microvesicles, and exosomes | Prostate | 2014 | 223 |
| 41 | Mechanisms of constitutive NF-κB activation in human prostate cancer cells | Prostate | 2002 | 221 |
| 42 | Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer | Prostate | 2002 | 220 |
| 43 | LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics | Prostate | 2017 | 219 |
| 44 | Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer | Prostate | 2013 | 217 |
| 45 | Expression of CCL5 (RANTES) and CCR5 in prostate cancer | Prostate | 2006 | 216 |
| 46 | Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy | Prostate | 2002 | 215 |
| 47 | Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate | Prostate | 2003 | 215 |
| 48 | Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response | Prostate | 2016 | 208 |
| 49 | Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines | Prostate | 1993 | 207 |
| 50 | Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer | Prostate | 2013 | 207 |
